ctDNA Test Guides Breast Care in Elderly
Blood-based monitoring may help tailor less invasive treatment decisions
-
1
ctDNA testing may help older women with breast cancer avoid surgery by relying on endocrine therapy alone.
-
2
The study found that persistent ctDNA after 6 months indicated tumor progression, while negative ctDNA at baseline showed no progression.
-
3
ctDNA serves as a minimally invasive biomarker, allowing for decentralized monitoring through routine blood draws.
-
4
Pretreatment ctDNA positivity is linked to higher progression risk, suggesting it could enhance traditional pathology markers.
-
5
If validated, ctDNA testing could lead to more personalized and less invasive breast cancer management strategies.
